Latest Industry Insights

A recent collaboration between Onconova Therapeutics and Mission will utilize the Mission Bio TapestriⓇ Platform to conduct targeted single-cell DNA analysis for the study of Onconova's novel cancer therapy, Rigosertib. We spoke with Darrin Crisitello, CCO of Mission Bio, to learn more.

Technology Networks recently visited Dresden, Germany, for Lipotype's Lipid Excellence Award press talk, where we gained insights into the past, present and future of lipidomics research.

Predicting the reprogramming factors necessary to induce cell conversion has largely relied on trial and error, revealing the need for a more systematic approach. To learn about Mogrify's approach to achieving cell conversion through transdifferentiation, we interviewed Pierre-Louis Joffrin, Corporate Development Executive at Mogrify.

Through a series of exclusive interviews with world-renowned scientists and bioethicists, Technology Networks Explores the CRISPR Revolution will investigate the ground-breaking research taking place in the CRISPR space, CRISPR "controversies" and whether the CRISPR technology looks set to fulfil its promise of revolutionizing science.

Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.

Technology Networks spoke with Dr Roman Fischer to learn more about the challenges researchers face in the field of clinical proteomics, and how 4D proteomics workflows are enhancing his laboratory's work.

10 things to note about viral vector manufacturing, regarding the complexities and challenges, and the technology that will help drive cell and gene therapy forward. Here we share insights from Pall and Molmed representatives, who are leaders in the fields of bioprocessing and cell and gene therapy.

Long sequences of DNA are a key requirement for researchers to be able to develop novel synthetic biomolecules. However, assembling long sequences can prove problematic and slow down the process of gene assembly. GenBrick™ utilizes a novel proprietary technology to enable accurate one-step DNA assembly. We spoke with Cedric Wu, Ph.D., GenScript Sr. Director of R&D to learn more about the capabilities of GenBrick™.

We recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific. Previously, Quagliata was involved in one of the first teams in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics. Here, he shares his perspectives on the field, particularly the use of NGS in the analysis of liquid biopsies, the discovery of cancer biomarkers and the potential application of artificial intelligence (AI) in molecular diagnostics.

We recently spoke with Dr Marian Rehak, VP of Research and Development at Sphere Fluidics, to learn more about the importance of single cell analysis. Marian touches on some of the common challenges encountered and highlights some of the key applications.